September
27
/ 2019
Safe’n’Sound® is on the market in Europe with a newly registered injectable medication.
The commercial launch of HULIO™ (Adalimumab Biosimilar) was initiated in selected European markets on October 19,2018.
Hulio™, developed by Fujifilm Kyowa Kirin Biologics Co., Ltd. and marketed in the European Union by Mylan N.V. is approved as a biosimilar for the same indications as the reference product, Humira®.
display_title
A new market reference added to Safe’n’Sound®, Nemera's passive safety device platform Safe’n’Sound
Categories